234 related articles for article (PubMed ID: 9564789)
41. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
42. Podophyllotoxin-resistant mutants of Chinese hamster ovary cells: cross-resistance studies with various microtubule inhibitors and podophyllotoxin analogues.
Gupta RS
Cancer Res; 1983 Feb; 43(2):505-12. PubMed ID: 6848174
[TBL] [Abstract][Full Text] [Related]
43. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.
Mulligan JM; Greene LM; Cloonan S; Mc Gee MM; Onnis V; Campiani G; Fattorusso C; Lawler M; Williams DC; Zisterer DM
Mol Pharmacol; 2006 Jul; 70(1):60-70. PubMed ID: 16571652
[TBL] [Abstract][Full Text] [Related]
44. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
[TBL] [Abstract][Full Text] [Related]
45. Mutagenesis of beta-tubulin cysteine residues in Saccharomyces cerevisiae: mutation of cysteine 354 results in cold-stable microtubules.
Gupta ML; Bode CJ; Dougherty CA; Marquez RT; Himes RH
Cell Motil Cytoskeleton; 2001 Jun; 49(2):67-77. PubMed ID: 11443737
[TBL] [Abstract][Full Text] [Related]
46. Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogues.
Blokhin AV; Yoo HD; Geralds RS; Nagle DG; Gerwick WH; Hamel E
Mol Pharmacol; 1995 Sep; 48(3):523-31. PubMed ID: 7565634
[TBL] [Abstract][Full Text] [Related]
47. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.
Buey RM; Barasoain I; Jackson E; Meyer A; Giannakakou P; Paterson I; Mooberry S; Andreu JM; Díaz JF
Chem Biol; 2005 Dec; 12(12):1269-79. PubMed ID: 16356844
[TBL] [Abstract][Full Text] [Related]
48. Microtubule assembly dynamics: an attractive target for anticancer drugs.
Singh P; Rathinasamy K; Mohan R; Panda D
IUBMB Life; 2008 Jun; 60(6):368-75. PubMed ID: 18384115
[TBL] [Abstract][Full Text] [Related]
49. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
50. 4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system.
Sengupta S; Smitha SL; Thomas NE; Santhoshkumar TR; Devi SK; Sreejalekshmi KG; Rajasekharan KN
Br J Pharmacol; 2005 Aug; 145(8):1076-83. PubMed ID: 15951833
[TBL] [Abstract][Full Text] [Related]
51. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
Bhattacharyya B; Panda D; Gupta S; Banerjee M
Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
[TBL] [Abstract][Full Text] [Related]
52. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.
Nunes M; Kaplan J; Wooters J; Hari M; Minnick AA; May MK; Shi C; Musto S; Beyer C; Krishnamurthy G; Qiu Y; Loganzo F; Ayral-Kaloustian S; Zask A; Greenberger LM
Biochemistry; 2005 May; 44(18):6844-57. PubMed ID: 15865430
[TBL] [Abstract][Full Text] [Related]
53. Cytoskeletons and antimitotic agents developed in Japan.
Nishio K; Saijo N
Anticancer Drug Des; 1999 Apr; 14(2):133-41. PubMed ID: 10405640
[TBL] [Abstract][Full Text] [Related]
54. Interaction of tubulin with a new fluorescent analogue of vinblastine.
Chatterjee SK; Laffray J; Patel P; Ravindra R; Qin Y; Kuehne ME; Bane SL
Biochemistry; 2002 Nov; 41(47):14010-8. PubMed ID: 12437358
[TBL] [Abstract][Full Text] [Related]
55. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
Cruz-Monserrate Z; Vervoort HC; Bai R; Newman DJ; Howell SB; Los G; Mullaney JT; Williams MD; Pettit GR; Fenical W; Hamel E
Mol Pharmacol; 2003 Jun; 63(6):1273-80. PubMed ID: 12761336
[TBL] [Abstract][Full Text] [Related]
56. Microtubule-disrupting effects of gallium chloride in vitro.
Perchellet EM; Ladesich JB; Collery P; Perchellet JP
Anticancer Drugs; 1999 Jun; 10(5):477-88. PubMed ID: 10477168
[TBL] [Abstract][Full Text] [Related]
57. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
Bai R; Friedman SJ; Pettit GR; Hamel E
Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
[TBL] [Abstract][Full Text] [Related]
58. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
59. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines.
McDaid HM; Bhattacharya SK; Chen XT; He L; Shen HJ; Gutteridge CE; Horwitz SB; Danishefsky SJ
Cancer Chemother Pharmacol; 1999; 44(2):131-7. PubMed ID: 10412947
[TBL] [Abstract][Full Text] [Related]
60. Effect of taxol on vinblastine sulfate-induced crystallization of tubulin.
Ohta S; Krishan A; Nishio K; Ohmori T; Kunikane H; Inomata M; Takahashi T; Saijo N
Anticancer Res; 1993; 13(4):873-7. PubMed ID: 7688938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
